A 62-Year-Old Woman With Metastatic BRAF V600E-Mutated NSCLC
Case: A 62-Year-Old Woman With MetastaticBRAFV600E-Mutated NSCLC
Initial Presentation
Clinical Workup
Treatment and Follow-Up
Bispecific Antibodies and ADCs Deliver a Futuristic Horizon Across Lung Cancer Settings
October 23rd 2024Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ivonescimab outperforming pembrolizumab in PD-L1-positive advanced non-small cell lung cancer.
Read More